ECSP045110A - Composiciones de la preparación que contiene un compuesto fisiologicamente activo de acidos inestables y procesos para su producción - Google Patents

Composiciones de la preparación que contiene un compuesto fisiologicamente activo de acidos inestables y procesos para su producción

Info

Publication number
ECSP045110A
ECSP045110A EC2004005110A ECSP045110A ECSP045110A EC SP045110 A ECSP045110 A EC SP045110A EC 2004005110 A EC2004005110 A EC 2004005110A EC SP045110 A ECSP045110 A EC SP045110A EC SP045110 A ECSP045110 A EC SP045110A
Authority
EC
Ecuador
Prior art keywords
composition
preparation
active compound
production
compositions
Prior art date
Application number
EC2004005110A
Other languages
English (en)
Inventor
Shigeru Aoki
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of ECSP045110A publication Critical patent/ECSP045110A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se tiene la intención de divulgar la composición de la preparación la cual permita la producción conveniente de la composición de la preparación de liberación sostenida que contiene un compuesto activo de ácidos fisiológicamente inestables y tiene las propiedades de liberación sostenida deseada. En especial, la composición de la preparación que comprende un núcleo que contiene un compuesto activo de ácidos fisiológicamente inestables y una capa con la cual el núcleo es revestido y el cual contiene una mezcla de un polímero insoluble en agua y un polímero entérico. La composición de la preparación según la actual invención permite mantener una concentración eficaz en la sangre del compuesto fisiológico activo durante mucho tiempo, mejorando de tal modo su efecto terapéutico. Además, la composición según la actual invención se mantiene estable durante almacenajes prolongados.
EC2004005110A 2001-11-21 2004-05-17 Composiciones de la preparación que contiene un compuesto fisiologicamente activo de acidos inestables y procesos para su producción ECSP045110A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001356018 2001-11-21

Publications (1)

Publication Number Publication Date
ECSP045110A true ECSP045110A (es) 2004-08-27

Family

ID=19167613

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005110A ECSP045110A (es) 2001-11-21 2004-05-17 Composiciones de la preparación que contiene un compuesto fisiologicamente activo de acidos inestables y procesos para su producción

Country Status (25)

Country Link
EP (1) EP1454634A4 (es)
JP (1) JP4540092B2 (es)
KR (1) KR20050044545A (es)
CN (2) CN1589156A (es)
AP (1) AP1919A (es)
AU (1) AU2002366029B2 (es)
BR (1) BR0214372A (es)
CA (1) CA2466726C (es)
CO (1) CO5580800A2 (es)
CR (1) CR7351A (es)
EC (1) ECSP045110A (es)
HU (1) HUP0402323A3 (es)
IL (2) IL161983A0 (es)
IS (1) IS7266A (es)
MA (1) MA26346A1 (es)
MX (1) MXPA04004775A (es)
NO (1) NO20042563L (es)
NZ (1) NZ532907A (es)
RO (1) RO122395B1 (es)
RU (1) RU2311906C2 (es)
SI (1) SI21447A (es)
TW (1) TWI302461B (es)
UA (1) UA76256C2 (es)
WO (1) WO2003043661A1 (es)
ZA (1) ZA200403551B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
NZ549838A (en) * 2004-03-26 2010-04-30 Eisai R&D Man Co Ltd Coated controlled-release preparation containing a gastric acid secretion inhibitor
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
AU2005299490C1 (en) 2004-10-21 2012-01-19 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US8481565B2 (en) 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
EP1858493A4 (en) * 2005-03-14 2010-12-01 Sun Pharmaceutical Ind Ltd SYSTEM FOR ORAL ADMINISTRATION OF MEDICINAL PRODUCTS
WO2006111853A2 (en) * 2005-04-18 2006-10-26 Aurobindo Pharma Limited Stable solid dosage forms of acid labile drug
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
WO2008062320A2 (en) * 2006-10-06 2008-05-29 Eisai R&D Management Co., Ltd Extended release formulations of a proton pump inhibitor
RU2414889C2 (ru) * 2007-11-16 2011-03-27 Общество С Ограниченной Ответственностью "Технология Лекарств" Фармацевтическая композиция для лечения язвы желудка и двенадцатиперстной кишки в форме твердых желатиновых капсул, содержащая рабепразол или его производные, и способ ее получения
JPWO2009069280A1 (ja) * 2007-11-27 2011-04-07 大原薬品工業株式会社 造粒物の製造法
CN101822671A (zh) * 2009-03-06 2010-09-08 信谊药厂 雷贝拉唑组合物及其制备方法
KR101765357B1 (ko) 2009-12-02 2017-08-04 아데어 파마수티컬스 에스.알.엘. 펙소페나딘 마이크로캡슐 및 그것을 함유하는 조성물
NZ605562A (en) * 2010-07-09 2013-11-29 Teijin Pharma Ltd Deuterated benzylbenzene derivatives and methods of use
JP2018184360A (ja) * 2017-04-25 2018-11-22 ニプロ株式会社 経口投与用の腸溶性徐放性製剤
KR102227486B1 (ko) * 2017-06-30 2021-03-12 롯데정밀화학 주식회사 프로톤 펌프 저해제를 포함하는 경구용 고형제제 조성물, 이를 포함하는 경구용 고형제제 및 그 제조방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
JPS5944311A (ja) * 1982-09-07 1984-03-12 Santen Pharmaceut Co Ltd 徐放性顆粒およびその製造法
EP0386967B1 (en) * 1989-03-10 1995-07-12 Yamanouchi Pharmaceutical Co. Ltd. A drug-release controlling coating material for long acting formulations
GB8926639D0 (en) * 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
EP0447168A3 (en) * 1990-03-16 1993-01-07 Yamanouchi Pharmaceutical Co. Ltd. Long acting granular pharmaceutical composition
JPH0826977A (ja) * 1994-07-19 1996-01-30 Tanabe Seiyaku Co Ltd 溶出制御型経口製剤
JPH09323926A (ja) * 1996-03-15 1997-12-16 Nikken Chem Co Ltd バルプロ酸ナトリウムの徐放性錠剤
ES2137862B1 (es) * 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
KR100627614B1 (ko) * 1998-04-20 2006-09-25 에자이 가부시키가이샤 안정화된 벤즈이미다졸계 화합물 함유 조성물로 이루어지는 의약제제
KR100554924B1 (ko) * 1998-05-18 2006-03-03 다케다 야쿠힌 고교 가부시키가이샤 구강내 붕괴 정제
JP2001055322A (ja) * 1999-08-18 2001-02-27 Tanabe Seiyaku Co Ltd パルス放出型製剤
CN1197574C (zh) * 1999-10-20 2005-04-20 卫材株式会社 稳定苯并咪唑化合物的方法
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems

Also Published As

Publication number Publication date
SI21447A (sl) 2004-10-31
CN1589156A (zh) 2005-03-02
MA26346A1 (fr) 2004-10-01
NZ532907A (en) 2007-05-31
IL161983A0 (en) 2005-11-20
UA76256C2 (en) 2006-07-17
TW200300353A (en) 2003-06-01
RU2311906C2 (ru) 2007-12-10
CA2466726C (en) 2011-02-22
HUP0402323A3 (en) 2008-04-28
HUP0402323A2 (hu) 2005-02-28
IL161983A (en) 2009-11-18
JP4540092B2 (ja) 2010-09-08
BR0214372A (pt) 2004-10-26
JPWO2003043661A1 (ja) 2005-03-10
ZA200403551B (en) 2005-07-07
CN101982199A (zh) 2011-03-02
CR7351A (es) 2005-05-12
AU2002366029A1 (en) 2003-06-10
MXPA04004775A (es) 2005-02-17
RO122395B1 (ro) 2009-05-29
WO2003043661A1 (fr) 2003-05-30
AP1919A (en) 2008-11-13
EP1454634A4 (en) 2007-05-30
AP2004003045A0 (en) 2004-06-30
TWI302461B (en) 2008-11-01
CO5580800A2 (es) 2005-11-30
KR20050044545A (ko) 2005-05-12
IS7266A (is) 2004-05-14
CA2466726A1 (en) 2003-05-30
NO20042563L (no) 2004-06-18
AU2002366029B2 (en) 2008-01-31
EP1454634A1 (en) 2004-09-08
RU2004118495A (ru) 2005-03-20

Similar Documents

Publication Publication Date Title
MX342613B (es) Geles con base de acido hialuronico que incluyen agentes anestesicos.
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
RU2013121788A (ru) Ингибиторы репликации вич
AR042340A1 (es) Liberacion controlada de una sustancia activa a un entorno rico en grasa
AR110986A2 (es) Composiciones de ecteinascidina, formulaciones liofilizadas, método de preparación y uso
AR109263A2 (es) Composición que comprende moxidectina
AR027091A1 (es) Forma de dosificacion de farmacos accionada por un hidrogel
PE20090605A1 (es) Composiciones de fenilalanina amoniaco-liasa procariotica y metodos del tratamiento del cancer usando composiciones de la misma
PA8575701A1 (es) Preparaciones acidas de insulina con estabilidad mejorada
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
CY1108992T1 (el) Η χρηση του υαλουρονικου οξεος για την παρασκευη συνθεσεων για τη θεραπευτικη αντιμετωπιση υποτροπιαζουσων αφθων της στοματικης κοιλοτητας
BR112012006283A2 (pt) formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte
MXPA05008382A (es) Acidos grasos, gliceridos y analogos con longitud de cadena media como estimuladores de eritropoyesis.
BR0014869A (pt) Composição e método para estabilização da mesma
NO20022201L (no) Lösninger inneholdende Epinastin
CR7351A (es) Composicion de la preparacion que contiene el compuesto fisiologico activo de acido inestable el proceso para producirla
DK1377164T3 (da) Erythropoietin forbedrer kemoterapi-induceret toksicitet in vivo
NO20023875L (no) Stabilt nasalt, oralt eller sublingualt anvendbart preparat
BR0109672A (pt) Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente
DE50211566D1 (de) Kombination ausgewählter opioide mit muscarin-antagonisten zur therapie der harninkontinenz
AR038141A1 (es) Composiciones farmaceuticas estables que comprenden inhibidor(es) de ace
DE60123100D1 (de) Honig enthaltende pharmazeutische zusammensetzung zur wundbehandlung
AR048050A1 (es) Formas de administracion masticables, no comprimidas, dosificadas individualmente
AR006892A1 (es) Uso de formas del acido hialuronico (ha) para el tratamiento del cancer